Table 2.
Univariate analysis of included patients by one-year clinical prognosis in general.
| Factors | Unfavorable clinical prognosis (n = 26) | Favorable clinical prognosis (n = 65) | p-value |
|---|---|---|---|
| Demographic | |||
| Age (years) | 71.92 ± 4.30 | 69.92 ± 3.62 | 0.027* |
| Sex (male, %) | 12 (45.15) | 32 (49.23) | 0.791 |
| CCI | 2.03 ± 0.87 | 1.46 ± 1.19 | 0.018* |
| Hypertension, n (%) | 7 (26.92) | 21 (32.31) | 0.615 |
| Smoking history, n (%) | 2 (7.69) | 8 (12.31) | 0.791 |
| Drinking history, n (%) | 6 (23.08) | 7 (10.77) | 0.236 |
| Duration of illness (months) | 3.73 ± 1.87 | 4.29 ± 2.40 | 0.287 |
| Duration of anti-TB agents (months) | 1.12 ± 0.66 | 1.33 ± 0.79 | 0.245 |
| ESR (mm/1 h) | 52.11 ± 12.57 | 47.35 ± 13.96 | 0.135 |
| CRP (mg/L) | 29.57 ± 6.28 | 28.14 ± 5.92 | 0.308 |
| Length of hospital day | 11.69 ± 3.82 | 10.80 ± 3.58 | 0.295 |
| GNRI | 96.21 ± 6.95 | 106.69 ± 8.19 | 0.000* |
| Vertebral body involvement | |||
| Abscess, n (%) | 15 (57.69) | 39(60.00) | 0.840 |
| Kyphotic deformity, n (%) | 10 (38.46) | 22 (33.85) | 0.677 |
| Number of involed verterbrae, n (%) | 0.574 | ||
| 1 | 2 (7.69) | 5 (7.69) | |
| 2–3 | 18 (69.23) | 51 (78.46) | |
| >3 | 6 (23.08) | 9 (13.85) | |
| Location of lesions, n (%) | 0.414 | ||
| Cervical | 5 (19.23) | 6 (9.23) | |
| Thoracic | 11 (42.31) | 30 (46.15) | |
| Lumbosacral | 10 (38.46) | 29 (44.62) | |
| Franked scale, n (%) | 0.671 | ||
| B | 0 (0.00) | 2 (3.08) | |
| C | 3 (11.54) | 9 (13.85) | |
| D | 7 (26.92) | 18(27.69) | |
| E | 16 (61.54) | 36 (55.38) | |
| Extra-osseous lesions, n (%) | 6 (23.08) | 12 (18.46) | 0.618 |
| Surgical factors | |||
| Operative time (minutes) | 197.70 ± 82.48 | 196.44 ± 76.31 | 0.945 |
| Estimated blood loss (mL) | 632.03 ± 304.81 | 625.33 ± 232.04 | 0.910 |
| Surgical approach, n (%) | 0.542 | ||
| Anterior | 9 (34.62) | 23 (35.38) | |
| Posterior | 12 (46.15) | 35 (53.85) | |
| Combined | 5 (19.23) | 7 (10.78) | |
| Fused vertebrae | 4.42 ± 1.45 | 4.57 ± 1.38 | 0.654 |
| Blood transfusion, n (%) | |||
| RBC | 14 (53.85) | 16 (24.61) | 0.007* |
| Plasma | 7(26.92) | 10 (15.38) | 0.202 |
| Complications, n (%) | 25 (96.15) | 15 (23.08) | 0.000* |
| Pneumonia | 9 (34.62) | 5 (7.69) | 0.024* |
| Pneumothorax | 5 (19.23) | 1 (1.54) | 0.009* |
| CSF leakage | 1 (3.85) | 1 (1.54) | 0.492 |
| VTE | 3 (11.54) | 2 (3.08) | 0.275 |
| UTI | 4 (15.38) | 3 (4.62) | 0.191 |
| Wound associated complications | 3 (11.54) | 2 (3.08) | 0.275 |
| Recurrence | 0 (0.00) | 1 (1.54) | 1.000 |
*p < 0.05, the difference between the unfavorable clinical prognosis group and the favorable clinical prognosis was significant.